» Articles » PMID: 39385163

Time to Death from Cervical Cancer and Its Predictors in Hospitalized Patients: a Survival Approach Study in Mato Grosso, Brazil

Overview
Publisher Biomed Central
Date 2024 Oct 9
PMID 39385163
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cervical cancer (CC) is a serious public health concern, being the fourth most common cancer among women and a leading cause of cancer mortality. In Brazil, many women are diagnosed late, and in Mato Grosso, with its geographical diversity, there are specific challenges. This study analyzed hospital survival and its predictors using data from the Hospital Information System (SIH) of the Unified Health System (SUS) in Mato Grosso from 2011 to 2023.

Methods: Cox regression and Kaplan-Meier models were applied to determine survival time and identify mortality predictors. The adjusted Hazard Ratio (AHR) with a 95% Confidence Interval (CI) was used to measure the association between the factors analyzed.

Results: The hospital mortality rate was 9.88%. The median duration of hospitalization was 33 days (interquartile range [IQR]: 12-36), with a median survival of 43.7%. Patients were followed up for up to 70 days. In the multivariable Cox model, after adjusting for potential confounders, the risk of death during hospitalization was higher in patients aged 40-59 years (AHR = 1.39, p = 0.027) and 60-74 years (AHR = 1.54, p = 0.007), in the absence of surgical procedures (AHR = 4.48, p < 0.001), in patients with medium service complexity (AHR = 2.40, p = 0.037), and in the use of ICU (AHR = 4.97, p < 0.001). On the other hand, patients with hospital expenses above the median (152.971 USD) showed a reduced risk of death (AHR = 0.21, p < 0.001).

Conclusion: This study highlights that hospitalized CC patients have reduced survival, underscoring the need for interventions to improve care, including strategies for early diagnosis and expanded access to adequately resourced health services.

References
1.
Rai S, Mishra P, Ghoshal U . Survival analysis: A primer for the clinician scientists. Indian J Gastroenterol. 2022; 40(5):541-549. PMC: 8743691. DOI: 10.1007/s12664-021-01232-1. View

2.
Xie S, Pan S, Zou S, Zhu H, Zhu X . Characteristics and Treatments of Patients Aged 65 Years or Over with Cervical Cancer. Clin Interv Aging. 2020; 15:841-851. PMC: 7293398. DOI: 10.2147/CIA.S255305. View

3.
Li H, Wu X, Cheng X . Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 2016; 27(4):e43. PMC: 4864519. DOI: 10.3802/jgo.2016.27.e43. View

4.
Portela , SCHRAMM , Pepe , Noronha , Pinto , Cianeli . [Algorithm for establishing hospital admittance data based on the hospital information system in the Brazilian Unified Health System]. Cad Saude Publica. 2000; 13(4):771-774. DOI: 10.1590/s0102-311x1997000400020. View

5.
Seifu B, Fikru C, Yilma D, Tessema F . Predictors of time to death among cervical cancer patients at Tikur Anbesa specialized hospital from 2014 to 2019: A survival analysis. PLoS One. 2022; 17(2):e0264369. PMC: 8870501. DOI: 10.1371/journal.pone.0264369. View